Moreover, genetic deletion or pharmacological inhibition of S100A8/A9 can inhibit the TLR4/NLRP3/IL-1β pathway, suppressing ischemia-induced granulopoiesis and improving cardiac dysfunction [16]. This evidence concerns the gene NLRP3 and ischemia.